Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Shattock: Novel Antigens for Mucosal Protection |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2011-06-27 |
| Study Made Public: | 2015-10-19 |
Title
Functional antibody and T cell responses in samples obtained from MUCOVAC02 human clinical trial
Description
CAVD 268 evaluates immune responses in samples from the MUCOVAC2 Phase I clinical trial, which assessed CN54 gp140 immunization at different doses with different routes and adjuvants.
Sign in to see full information about this study and to download study data.
Products
GLA-AF Chitosan CN54 gp140 Gel 2734Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.